Last updated: February 20, 2026
What is the drug identified by NDC 58657-0500?
NDC 58657-0500 corresponds to Dorzolamide Hydrochloride Ophthalmic Solution 2%. This medication is used to reduce elevated intraocular pressure in conditions such as glaucoma and ocular hypertension. It functions as a carbonic anhydrase inhibitor to decrease aqueous humor production.
Market Size and Demand Drivers
Current Market Overview
The global glaucoma therapeutics market was valued at approximately USD 5.5 billion in 2022 and is expected to reach USD 8.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1%. The increase stems from aging populations and rising prevalence of glaucoma.
Key Demand Factors
- Prevalence: Over 76 million people worldwide suffer from glaucoma, with aging and diabetes contributing to higher incidences.
- Existing Treatments: Prostaglandin analogs dominate the market, but patients often require combination therapy, creating demand for adjunct drugs like dorzolamide.
- Market Penetration: As a generic, dorzolamide faces competition from newer formulations with fewer side effects, but it remains a low-cost option in many regions.
Competitive Landscape
Major competitors include:
- Brimonidine
- Timolol
- Carbonic anhydrase inhibitors like brinzolamide
- Fixed-combination drugs combining multiple agents
Generic availability limits upper price bounds but sustains steady volume sales.
Regulatory Status and Market Access
- FDA Approval: Approved since 1995.
- Patent Status: Lapsed; generic formulations available since the late 2000s.
- Pricing Policies: Price varies widely across regions, influenced by healthcare policies, insurance coverage, and market competition.
Price Trends and Projection
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 10 mL unit |
Notes |
| 2018 |
USD 40 |
Mid-tier generic price |
| 2020 |
USD 33 |
Price declines with increased competition |
| 2022 |
USD 28 |
Lower prices driven by generic saturation |
Future Price Forecast (2023-2030)
| Year |
Estimated AWP per 10 mL |
Assumptions |
| 2023 |
USD 25 |
Continued generic competition |
| 2025 |
USD 22 |
Slight price decrease as market matures |
| 2030 |
USD 20 |
Stabilization at lower price levels |
Price trends assume increased market saturation and price sensitivity, particularly in developed countries.
Factors Influencing Future Pricing
- Regulatory changes: Facilitating or hindering price controls.
- Market entry of novel therapies: Reducing dependence on older drugs.
- Generic manufacturer strategies: Price competition to gain market share.
- Healthcare reimbursement policies: Preference for cost-effective treatments.
Revenue Projections
Assuming steady demand with annual sales volumes of approximately 3 million units globally, revenue from this NDC could be estimated as follows:
| Year |
Estimated Sales Volume |
Price per 10 mL |
Estimated Revenue |
| 2023 |
3 million units |
USD 25 |
USD 75 million |
| 2025 |
3 million units |
USD 22 |
USD 66 million |
| 2030 |
3 million units |
USD 20 |
USD 60 million |
Notes
- Sales volume projections are conservative, considering holistic market trends.
- Price adjustments reflect generic competition and regulatory impacts.
Key Takeaways
- The drug’s market is mature, with a stable but declining price trend due to increased generic competition.
- Revenue potential remains sizable, especially in emerging markets where affordability drives demand.
- Price projections indicate continued decline toward USD 20-22 per 10 mL by 2025-2030.
- Market growth depends on demographic trends, regulatory shifts, and the introduction of new treatment options.
FAQs
1. What are the main competitors for NDC 58657-0500?
Prostaglandin analogs, timolol, brimonidine, and combination therapies.
2. How does pricing vary across regions?
Prices are higher in the US and Europe due to regulatory and reimbursement structures, while developing countries benefit from lower generic prices.
3. Will patent status affect future pricing?
Since patents have expired, generic competition dominates, exerting downward pressure on prices.
4. What potential factors could disrupt current price trends?
Introduction of new drugs with better efficacy or safety profiles, regulatory price controls, or shifts in healthcare policies.
5. Which markets offer the greatest growth opportunities?
Emerging markets in Asia and Latin America, driven by increasing glaucoma prevalence and cost-sensitive healthcare systems.
References
- MarketWatch. (2022). Glaucoma therapeutics market size, share, growth, and forecast.
- FDA. (1995). Approval documentation for dorzolamide ophthalmic solution.
- IQVIA. (2022). Global ophthalmic drug sales report.
- World Health Organization. (2021). Global prevalence of glaucoma.
- Bloomberg Industry Research. (2023). Ophthalmic drugs market projections.
